• 1

    Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576-588.

    • Search Google Scholar
    • Export Citation
  • 2

    Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.

  • 3

    Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-721.

  • 4

    Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:2736-2740.

    • Search Google Scholar
    • Export Citation
  • 5

    Park EK, Takahashi K, Hoshuyama T. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 2011;119:514-518.

  • 6

    Malignant mesothelioma mortality—United States, 1999-2005. MMWR Morb Mortal Wkly Rep 2009;58:393-396.

  • 7

    Nishikawa K, Takahashi K, Karjalainen A. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect 2008;116:1675-1680.

    • Search Google Scholar
    • Export Citation
  • 8

    Larson T, Melnikova N, Davis SI, Jamison P. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999-2002. Int J Occup Environ Health 2007;13:398-403.

    • Search Google Scholar
    • Export Citation
  • 9

    Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107-112.

    • Search Google Scholar
    • Export Citation
  • 10

    Peto J, Decarli A, La Vecchia C. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672.

  • 11

    Leigh J, Davidson P, Hendrie L, Berry D. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002;41:188-201.

  • 12

    Travis LB, Fossa SD, Schonfeld SJ. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-1365.

    • Search Google Scholar
    • Export Citation
  • 13

    Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007;109:1432-1438.

  • 14

    De Bruin ML, Burgers JA, Baas P. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 2009;113:3679-3681.

  • 15

    Cavazza A, Travis LB, Travis WD. Post-irradiation malignant mesothelioma. Cancer 1996;77:1379-1385.

  • 16

    Witherby SM, Butnor KJ, Grunberg SM. Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer 2007;57:410-413.

  • 17

    Carbone M, Baris YI, Bertino P. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A 2011;108:13618-13623.

    • Search Google Scholar
    • Export Citation
  • 18

    Testa JR, Cheung M, Pei J. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-1025.

  • 19

    Allen RK, Cramond T, Lennon D, Waterhouse M. A retrospective study of chest pain in benign asbestos pleural disease. Pain Med 2011;12:1303-1308.

  • 20

    Ameille J, Brochard P, Letourneux M. Asbestos-related cancer risk in patients with asbestosis or pleural plaques. Rev Mal Respir 2011;28:e11-17.

    • Search Google Scholar
    • Export Citation
  • 21

    van Meerbeeck JP, Hillerdal G. Screening for mesothelioma: more harm than good? Am J Respir Crit Care Med 2008;178:781-782.

  • 22

    Roberts HC, Patsios DA, Paul NS. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 2009;4:620-628.

    • Search Google Scholar
    • Export Citation
  • 23

    Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:97-104.

  • 24

    Aberle DR, Adams AM, Berg CD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.

  • 25

    Gadgeel S, Pass H. Malignant mesothelioma. Commun Oncol 2006;3:215-224.

  • 26

    Kao SC, Yan TD, Lee K. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol 2011;6:602-605.

    • Search Google Scholar
    • Export Citation
  • 27

    Greillier L, Cavailles A, Fraticelli A. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007;110:2248-2252.

    • Search Google Scholar
    • Export Citation
  • 28

    Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006;129:362-368.

    • Search Google Scholar
    • Export Citation
  • 29

    Schneider T, Reimer P, Storz K. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg 2009;57:42-46.

    • Search Google Scholar
    • Export Citation
  • 30

    Zahid I, Routledge T, Bille A, Scarci M. What is the best treatment for malignant pleural effusions? Interact Cardiovasc Thorac Surg 2011;12:818-823.

    • Search Google Scholar
    • Export Citation
  • 31

    Arapis K, Caliandro R, Stern JB. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc 2006;20:919-923.

    • Search Google Scholar
    • Export Citation
  • 32

    Schneider J, Hoffmann H, Dienemann H. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317-1324.

    • Search Google Scholar
    • Export Citation
  • 33

    Luo L, Shi HZ, Liang QL. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a metaanalysis. Respir Med 2010;104:149-156.

    • Search Google Scholar
    • Export Citation
  • 34

    Hollevoet K, Nackaerts K, Thimpont J. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-625.

    • Search Google Scholar
    • Export Citation
  • 35

    Wheatley-Price P, Yang B, Patsios D. Soluble mesothelinrelated peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-3322.

    • Search Google Scholar
    • Export Citation
  • 36

    Creaney J, Yeoman D, Demelker Y. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-857.

    • Search Google Scholar
    • Export Citation
  • 37

    Grigoriu BD, Scherpereel A, Devos P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-2935.

    • Search Google Scholar
    • Export Citation
  • 38

    Pass HI, Lott D, Lonardo F. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-1573.

  • 39

    Cristaudo A, Foddis R, Vivaldi A. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-5081.

    • Search Google Scholar
    • Export Citation
  • 40

    Husain AN, Colby TV, Ordonez NG. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-1331.

    • Search Google Scholar
    • Export Citation
  • 41

    Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007;38:1-16.

    • Search Google Scholar
    • Export Citation
  • 42

    Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009;136:888-896.

  • 43

    de Perrot M, Feld R, Cho BC. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.

    • Search Google Scholar
    • Export Citation
  • 44

    Krug LM, Pass HI, Rusch VW. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.

    • Search Google Scholar
    • Export Citation
  • 45

    Bolukbas S, Manegold C, Eberlein M. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/permetrexed and radiotherapy. Lung Cancer 2011;71:75-81.

    • Search Google Scholar
    • Export Citation
  • 46

    Weder W, Stahel RA, Bernhard J. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202.

    • Search Google Scholar
    • Export Citation
  • 47

    Sugarbaker DJ, Flores RM, Jaklitsch MT. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.

    • Search Google Scholar
    • Export Citation
  • 48

    Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:159-163.

  • 49

    Baldini EH. External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 2004;14:543-548.

  • 50

    Ahmadzadehfar H, Palmedo H, Strunk H. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer 2007;58:418-421.

  • 51

    Nguyen NC, Tran I, Hueser CN. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med 2009;34:886-890.

    • Search Google Scholar
    • Export Citation
  • 52

    Pilling J, Dartnell JA, Lang-Lazdunski L. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg 2010;58:215-219.

    • Search Google Scholar
    • Export Citation
  • 53

    Rice DC, Steliga MA, Stewart J. Endoscopic ultrasoundguided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg 2009;88:862-868; discussion 868-869.

    • Search Google Scholar
    • Export Citation
  • 54

    Pilling JE, Stewart DJ, Martin-Ucar AE. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2004;25:497-501.

    • Search Google Scholar
    • Export Citation
  • 55

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th edition. New York: Springer; 2010.

  • 56

    Wilcox BE, Subramaniam RM, Peller PJ. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009;10:244-248.

    • Search Google Scholar
    • Export Citation
  • 57

    Flores RM, Akhurst T, Gonen M. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003;126:11-16.

    • Search Google Scholar
    • Export Citation
  • 58

    Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology 2005;10:649-655.

  • 59

    Schulze M, Boehle AS, Kurdow R. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001;71:1809-1812.

    • Search Google Scholar
    • Export Citation
  • 60

    Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting. Cancer 1995;75:801-805.

    • Search Google Scholar
    • Export Citation
  • 61

    Rice D, Rusch V, Pass H. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol 2011;6:1304-1312.

    • Search Google Scholar
    • Export Citation
  • 62

    Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:201-216.

  • 63

    Kindler HL. Surgery for mesothelioma? The debate continues. Lancet Oncol 2011;12:713-714.

  • 64

    Rice D. Surgical therapy of mesothelioma. Recent Results Cancer Res 2011;189:97-125.

  • 65

    Maziak DE, Gagliardi A, Haynes AE. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-169.

    • Search Google Scholar
    • Export Citation
  • 66

    Hasani A, Alvarez JM, Wyatt JM. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010-1016.

    • Search Google Scholar
    • Export Citation
  • 67

    Zahid I, Sharif S, Routledge T, Scarci M. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:812-817.

    • Search Google Scholar
    • Export Citation
  • 68

    Shahin Y, Wellham J, Jappie R. How successful is lungpreserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis. Eur J Cardiothorac Surg 2011;39:360-363.

    • Search Google Scholar
    • Export Citation
  • 69

    Flores RM, Pass HI, Seshan VE. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.

    • Search Google Scholar
    • Export Citation
  • 70

    Sugarbaker DJ, Jaklitsch MT, Bueno R. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-146.

    • Search Google Scholar
    • Export Citation
  • 71

    Yan TD, Boyer M, Tin MM. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-624.

    • Search Google Scholar
    • Export Citation
  • 72

    Schipper PH, Nichols FC, Thomse KM. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008;85:257-264; discussion 264.

    • Search Google Scholar
    • Export Citation
  • 73

    Treasure T, Lang-Lazdunski L, Waller D. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-772.

    • Search Google Scholar
    • Export Citation
  • 74

    Treasure T, Waller D, Tan C. The Mesothelioma and Radical Surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol 2009;4:1254-1258.

    • Search Google Scholar
    • Export Citation
  • 75

    Sharif S, Zahid I, Routledge T, Scarci M. Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:1040-1045.

    • Search Google Scholar
    • Export Citation
  • 76

    Yan TD, Cao CQ, Boyer M. Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Ann Thorac Cardiovasc Surg 2011;17:243-249.

    • Search Google Scholar
    • Export Citation
  • 77

    Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:163-172.

  • 78

    Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg 2009;21:149-153.

    • Search Google Scholar
    • Export Citation
  • 79

    Luckraz H, Rahman M, Patel N. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg 2010;37:552-556.

    • Search Google Scholar
    • Export Citation
  • 80

    Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 2011;73:256-263.

  • 81

    Ellis P, Davies AM, Evans WK. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1:591-601.

    • Search Google Scholar
    • Export Citation
  • 82

    Vogelzang NJ, Rusthoven JJ, Symanowski J. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.

    • Search Google Scholar
    • Export Citation
  • 83

    Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005;19:1117-1136, vii.

  • 84

    Katirtzoglou N, Gkiozos I, Makrilia N. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010;11:30-35.

    • Search Google Scholar
    • Export Citation
  • 85

    Ceresoli GL, Zucali PA, Favaretto AG. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443-1448.

    • Search Google Scholar
    • Export Citation
  • 86

    Castagneto B, Botta M, Aitini E. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-373.

    • Search Google Scholar
    • Export Citation
  • 87

    van Haarst JMW, Baas P, Manegold C. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-345.

    • Search Google Scholar
    • Export Citation
  • 88

    Nowak AK, Byrne MJ, Williamson R. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-496.

    • Search Google Scholar
    • Export Citation
  • 89

    Santoro A, O'Brien ME, Stahel RA. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756-763.

    • Search Google Scholar
    • Export Citation
  • 90

    Scagliotti GV, Shin DM, Kindler HL. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.

    • Search Google Scholar
    • Export Citation
  • 91

    Taylor P, Castagneto B, Dark G. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3:764-771.

    • Search Google Scholar
    • Export Citation
  • 92

    Muers MF, Stephens RJ, Fisher P. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-1694.

    • Search Google Scholar
    • Export Citation
  • 93

    Jassem J, Ramlau R, Santoro A. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.

    • Search Google Scholar
    • Export Citation
  • 94

    Stebbing J, Powles T, McPherson K. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009;63:94-97.

    • Search Google Scholar
    • Export Citation
  • 95

    Manegold C, Symanowski J, Gatzemeier U. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-927.

    • Search Google Scholar
    • Export Citation
  • 96

    Ceresoli GL, Zucali PA, Gianoncelli L. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:2-32.

  • 97

    Yajnik S, Rosenzweig KE, Mychalczak B. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003;56:1319-1326.

    • Search Google Scholar
    • Export Citation
  • 98

    Rusch VW, Rosenzweig K, Venkatraman E. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.

    • Search Google Scholar
    • Export Citation
  • 99

    Gupta V, Mychalczak B, Krug L. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-1052.

    • Search Google Scholar
    • Export Citation
  • 100

    Gupta V, Krug LM, Laser B. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 2009;4:746-750.

    • Search Google Scholar
    • Export Citation
  • 101

    Baldini EH, Recht A, Strauss GM. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-338.

    • Search Google Scholar
    • Export Citation
  • 102

    Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754-758.

    • Search Google Scholar
    • Export Citation
  • 103

    de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura—a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999;43:511-516.

    • Search Google Scholar
    • Export Citation
  • 104

    Di Salvo M, Gambaro G, Pagella S. Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma. Acta Oncol 2008;47:1094-1098.

    • Search Google Scholar
    • Export Citation
  • 105

    Davies HE, Musk AW, Lee YC. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Curr Opin Pulm Med 2008;14:326-330.

    • Search Google Scholar
    • Export Citation
  • 106

    O'Rourke N, Garcia JC, Paul J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007;84:18-22.

    • Search Google Scholar
    • Export Citation
  • 107

    Bydder S, Phillips M, Joseph DJ. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004;91:9-10.

    • Search Google Scholar
    • Export Citation
  • 108

    Rice DC, Stevens CW, Correa AM. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-1692; discussion 1692-1683.

    • Search Google Scholar
    • Export Citation
  • 109

    Rice DC, Smythe WR, Liao Z. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:350-357.

    • Search Google Scholar
    • Export Citation
  • 110

    Allen AM, Czerminska M, Janne PA. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-645.

    • Search Google Scholar
    • Export Citation
  • 111

    Kristensen CA, Nottrup TJ, Berthelsen AK. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009;92:96-99.

    • Search Google Scholar
    • Export Citation
  • 112

    Miles EF, Larrier NA, Kelsey CR. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 2008;71:1143-1150.

    • Search Google Scholar
    • Export Citation
  • 113

    Krayenbuehl J, Oertel S, Davis JB, Ciernik IF. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys 2007;69:1593-1599.

    • Search Google Scholar
    • Export Citation
  • 114

    Waite K, Gilligan D. The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol) 2007;19:182-187.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 322 240 7
PDF Downloads 30 19 3
EPUB Downloads 0 0 0